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Abstract
Apolipoprotein F (apoF) is 29 kilodalton secreted sialoglycoprotein that resides on the HDL and LDL fractions of human
plasma. Human ApoF is also known as Lipid Transfer Inhibitor protein (LTIP) based on its ability to inhibit cholesteryl ester
transfer protein (CETP)-mediated transfer events between lipoproteins. In contrast to other apolipoproteins, ApoF is
predicted to lack strong amphipathic alpha helices and its true physiological function remains unknown. We previously
showed that overexpression of Apolipoprotein F in mice reduced HDL cholesterol levels by 20–25% by accelerating
clearance from the circulation. In order to investigate the effect of physiological levels of ApoF expression on HDL
cholesterol metabolism, we generated ApoF deficient mice. Unexpectedly, deletion of ApoF had no substantial impact on
plasma lipid concentrations, HDL size, lipid or protein composition. Sex-specific differences were observed in hepatic
cholesterol content as well as serum cholesterol efflux capacity. Female ApoF KO mice had increased liver cholesteryl ester
content relative to wild type controls on a chow diet (KO: 3.4+/20.9 mg/dl vs. WT: 1.2+/20.3 mg/dl, p,0.05). No differences
were observed in ABCG1-mediated cholesterol efflux capacity in either sex. Interestingly, ApoB-depleted serum from male
KO mice was less effective at promoting ABCA1-mediated cholesterol efflux from J774 macrophages relative to WT controls.
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Introduction
Apolipoprotein F (apo F) is an HDL-associated protein that
bears no structural or sequence similarity to the other classical
apolipoproteins [1,2]. This includes the absence of strong
predicted amphipathic alpha helices which are essential for the
lipid binding properties of other HDL-associated apolipoproteins
such as apo A-I, apo A-II, apo E and the apo Cs [3,4]. Apo F is a
highly acidic secreted sialoglycoprotein [5] which was originally
described as lipid transfer inhibitor protein (LTIP), based on its
ability to inhibit cholesteryl ester transfer protein (CETP) activity
ex vivo [6,7,8,9,10]. LDL-associated apo F has been shown to
selectively inhibit CETP-mediated transfer events involving the
LDL particle [11,12]. The function of HDL-associated apo F,
which represents greater than 75% of the total plasma pool
[13,14], is currently not known. The genes for Apolipoprotein A-I
(ApoA-I) and ApoF have both been found in nearly every
mammalian and fish species examined [15,16,17]. Likewise the
CETP gene also exists in fish, but is absent in mice and rats [18]
and functionally defective in several other mammals- pigs, cows,
horses and dogs [19]. This lack of a consistent requirement for
plasma CE transfer activity across species suggests that ApoF has
been conserved throughout evolution for a purpose distinct from
CETP inhibition.
Recent proteomics studies have identified over 50 unique
proteins as bona fide components of HDL [20,21,22]. Surprisingly,
many of these proteins have no known role in lipid transport, but
instead are believed to participate in processes as diverse as
protease inhibition, complement activation, inflammation, platelet
function, and innate immunity [20]. It has been suggested that
these proteins are organized into subclasses where an HDL
particle may contain several related proteins that act cooperatively
to perform their function [23,24]. Interrogating the roles of these
individual HDL proteins is an important endeavor if we are to
understand the diverse functions of HDL, and its inverse
relationship to cardiovascular disease. We previously showed that
overexpression of both mouse and human apo F reduced HDL
cholesterol levels by 20–25% in mice [14], suggesting that apo F
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31616may be an important new player in HDL metabolism. In addition,
plasma from mice overexpressing apoF had an improved ability to
accept cholesterol from the macrophage per HDL-C. To
investigate the physiological relevance of these findings, we
knocked out the ApoF gene in mice. We report that mice with
targeted deletion of the ApoF gene are viable and fertile, and
exhibit no major perturbations in HDL cholesterol concentrations,
size, lipid or protein composition. The only lipid change observed
was an increase in hepatic cholesterol content in the Female ApoF
KO mice. Despite the lack of effects on HDL quantity, size and
composition, we found that ApoB-depleted sera from the male
ApoF KO mice had a reduced ability to promote cholesterol efflux
via the ABCA1 transporter relative to WT controls.
Results
Apo F is a secreted protein known to be highly expressed in
hamster and human liver- two species with endogenous CETP
expression. We used real time RT-PCR to evaluate the expression
pattern of apo F in mice, a species without a functional CETP
gene. We found that mouse ApoF is virtually exclusively liver-
expressed, with message levels ranging from low to undetectable in
the other whole tissues that were examined. (Figure 1A and 1B). In
the liver, ApoF was detected at a threshold cycle (Ct) of 21.9,
appearing just before b-Actin (Ct=22.2). ApoF was detectable in
the testes (Ct=30.9) adrenals (Ct=31.5), and ovaries (Ct=33.5) at
levels less than 0.6% of that seen in the liver. (Standard curves and
Ct values for all tissues are included in Figure S1, and Table S1
and Table S2.)
Mouse apo F is highly homologous to human ApoF (61%
identity at the amino acid level), and contains a consensus Furin
cleavage site (RAKRQS) where the proprotein region is cleaved to
liberate the mature C-terminal fragment of the protein (Figure 2A).
We found that mouse apo F utilizes a less common motif (NCS) for
glycosylation at asparagine 206. It should be noted that this
glycosylation site is in a different location than the N-linked site in
the mature human apo F protein which lies at N267 (relative to the
initiator Methionine) [14,25]. We found that this glycosylation site
at N206 in mouse apo F is nearly completely utilized when
ectopically expressed in HEK293 cells (Figure 2B), as shown by
the apparent 5 kDa drop in molecular weight when it is mutated
to alanine. In addition to N-linked carbohydrate modification,
human apo F is known to be extensively modified with O-linked
sugars. Mature mouse apo F has a predicted molecular weight of
17.5 kDa for the mature protein, in contrast to the roughly
32 kDa band (excluding 5 kDa V5-His Tag) that we observe in
conditioned media or mouse plasma. We treated plasma from
mice overexpressing apoF using our liver-specific AAV-vector, to
evaluate its size and glycosylation pattern (Figure 2C). Molecular
weight was reduced in a stepwise fashion from 32 to 22 kDa when
digested sequentially with PNGAseF, Sialidase A, and O-glycanase
confirming that like human ApoF, mouse ApoF is also extensively
modified with O-linked carbohydrate. Apo F is encoded by a small
two exon gene located on mouse chromosome 10qD3, a region
orthologous to human chromosome 12q13.3. The entire coding
sequence and intron of the murine ApoF gene was replaced with a
targeting cassette containing a B-galactosidase reporter gene
(Figure 3A). The depicted sequence of Exon 1 and 2 represents
remaining segments of the 59 and 39 untranslated regions
respectively. Southern blotting was used to confirm the deletion
and proper genomic location of the null allele. Digestion of the
ApoF locus with BamHI yields a 3.9 kb fragment for the wild type
allele, and a 2.4 kb fragment for the null allele when probed with a
radiolabeled probe that hybridizes just downstream of the gene
(Figure 3B). The defective ApoF allele was introduced into
C57BL6-derived ES cells. The apo F mouse colony was generated
and maintained on a pure C57BL6 background by breeding a
male chimeric founder with C57BL6/J female mice and
interbreeding the F1 progeny. Successful knockout of the apo F
message was confirmed by realtime RT-PCR. As expected, apo F
mRNA was reduced by 50% in the livers of the heterozygous
mice, and was undetectable in the knockout mice (Figure 3C).
Since the ApoF gene was replaced with a beta-galactosidase (B-
Gal) reporter gene, we also performed X-gal staining to examine
the expression pattern of B-Gal in tissues from adult mice
(Figure 4). As expected from real time RT-PCR analysis for ApoF,
impressive dark blue staining was evident in the livers of the ApoF
KO mice. Some staining could be observed in the kidneys, testes
and caudate epididymis after a prolonged incubation with the X-
gal substrate, however these were equally blue in the WT control
mice.
Figure 1. Tissue expression, processing and glycosylation of
murine apolipoprotein F. A. Real time RT-PCR analysis of total RNA
from tissues of female mice: brain, heart, lung, liver, spleen, kidney,
duodenum, jejunum, ileum, inguinal fat, brown fat, adrenals, thyroid,
and ovaries. B. Real time RT-PCR analysis of total RNA from tissues of
male mice: brain, heart, lung, liver, spleen, kidney, duodenum, jejunum,
ileum, inguinal fat, brown fat, stomach and testes. Values are shown as
the mean +/2 standard deviation for each animal (n=3 per group).
doi:10.1371/journal.pone.0031616.g001
Apolipoprotein F Knockout Mice
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deficient mice on a standard chow diet (Table 1). Female ApoF
KO mice had total cholesterol, HDL cholesterol, non-HDL
cholesterol, triglyceride, cholesteryl ester (CE) levels that were
identical to wild type mice (Table 1). Female ApoF KO mice
tended to have lower free cholesterol levels in the plasma, although
this did not always reach statistical significance (KO: 32+/29 vs.
WT: 38+/210 mg/dl, p.0.05). Female heterozygotes had
plasma lipid values identical to wild type levels, with the exception
of a very modest increase in CE content relative to that of the WT
and KO mice (Het: 54+/210 vs. WT: 45+/29 mg/dl, p,0.05).
Likewise, Male ApoF KO mice had total cholesterol, HDL
cholesterol, non-HDL cholesterol, cholesteryl ester (CE), and free
cholesterol (FC) values that were indistinguishable from wild type
littermates. The male ApoF KO mice did have fasting triglyceride
levels that were modestly but significantly lower than controls
(KO: 33+/211 vs WT: 43+/218 mg/dl). The male ApoF
heterozygous mice had marginally higher HDL cholesterol (Het:
70+/27 vs. WT: 62+/29 mg/dl), and cholesterol ester content
(Het: 56+/28 vs. WT: 50+/27 mg/dl) relative to wild type mice.
Body weight, liver weight, and liver somatic index were not
significantly altered in the ApoF knockout mice (Table 1), and did
not vary with aging. Interestingly, female ApoF KO mice
consistently had higher liver cholesterol levels on a chow diet
(KO: 4.9+/20.8 mg/dl vs. WT 2.9+/20.2 mg/dl, p,0.05). This
was entirely attributable to an increase in cholesteryl ester content
(KO 3.4+/20.9 mg/dl vs. WT 1.2+/20.3 mg/dl, p,0.05), while
liver free cholesterol (FC) content was unchanged (Table 1). The
male mice had a trend towards increased hepatic cholesterol
content, however this did not reach statistical significance in any of
our experiments (Table 1). Classical blood chemistry parameters
including sodium, postassium, creatinine, blood urea nitrogen
(BUN), aspartate aminotransferase (AST), and alanine amino-
transferase (ALT) were not different by genotype, and fell within
the expected reference intervals for mice (Table 2).
We made multiple attempts to evoke a lipoprotein phenotype in
the ApoF KO mice using dietary manipulations. Female mice
were fed a high fat (HF) diet containing 45% kCal from fat for 9
weeks. Plasma lipids were measured in the fasting state at baseline,
and after 2, 4, and 9 weeks of HF feeding (Table 3). In this
particular experiment, the female ApoF KO mice did exhibit
significantly lower FC levels at baseline on the chow diet (KO:
23+/22 vs. WT: 29+/26 mg/dl, p,0.05). We observed robust
increases in total cholesterol, HDL cholesterol, non HDL-C, CE,
and FC after just two weeks of feeding which were maintained
throughout the 9 week study for all genotypes (Time p,0.0001 by
two way ANOVA). Surprisingly, the difference in FC seen in the
ApoF KO mice was completely negated by the diet. At the two
and four week time points, the ApoF Het and KO mice both had
TG levels significantly lower than WT. There were no significant
differences in weight gain, adipose tissue mass, or food con-
sumption by genotype on the HF diet (data not shown). In further
attempts to elicit a lipoprotein difference, we performed short term
feeding to specifically test the effects of cholesterol loading or
depletion (Table 4). Female mice were fed chow containing 0.2%
cholesterol (w/w) or 0.01% ezetimibe (w/w) for 11 days. Neither
Figure 2. Glycosylation, processing and secretion of the mouse apo F protein. A. Schematic of the mouse apo F precursor protein depicting
the predicted boundaries of the signal peptide, proprotein region, and furin cleavage site (RAKR/S). The N-linked glycosylation site at N206 is shown
with a diamond. B. Western blot for mouse apo F in cells (left) and media (right), from HEK293 cells transiently transfected with either green
fluorescent protein (GFP), wild type mouse ApoF (mApoF), or mouse apo F with asparagine 206 mutated to alanine (N206A). C. Western blot of apo F
in one microliter of plasma from mice overexpressing mApoF from a liver-specific AAV vector. Plasma was denatured with heat and then subjected
with deglycosylation by PNGase F, Sialidase A, and O-glycanase. The mature and pro-fragment portions of the apo F protein are shown with arrows.
doi:10.1371/journal.pone.0031616.g002
Apolipoprotein F Knockout Mice
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ezetimibe had any measurable impact plasma lipids; with the
exception of a small but statistically significant difference in TG on
the ezetimibe diet (KO: 30+/24 vs WT: 38+/26 mg/dl,
p,0.05). Liver cholesterol levels trended higher in the ApoF
KO relative to WT mice on both diets, but did not reach statistical
significance in this experiment (Table 4).
In human plasma, greater than 75% of the circulating apo F is
found on HDL. We next examined the effect of apo F deficiency
on HDL quantity, size and lipid composition. Gel filtration
chromatography revealed a lipoprotein profile indistinguishable
from that of the wild type mice (Figure 5A). The cholesterol
content of the HDL peak was identical in height and area, and
there was no shift that would suggest changes in particle size.
Analysis of HDL particles by NMR confirmed that HDL size was
unchanged in the knockout mice (Figure 5B). Next we isolated
lipoproteins from these mice by KBr density gradient ultracentri-
fugation. There were no significant differences in the lipid or total
protein content of HDL (1.063,d,1.21), nor were there
differences in the composition of VLDL (d,1.006) or IDL/LDL
(1.006,d,1.063) (Table 5). Lastly, we subjected the proteins from
the isolated mouse HDL to SDS-PAGE to examine the apoprotein
composition (Figure 5C). We observed no differences in the
abundance of the major protein components of HDL. It should be
noted that mouse ApoF should have a molecular weight of 32 kDa
based on our overexpression studies. Endogenous apo F may exist
below the limit of detection, or more likely is obscured by the far
more abundant apo A-I band (29 kDa). One band that differed
greatly between the groups at ,13 kDa was excised from the gel
for identification by LC-MS. This band was found to contain
apolipoprotein N (apo N) and Beta-Globin as the main protein
components.
We previously reported that HDL from mice overexpressing
ApoF had an increased ability to accept macrophage derived
cholesterol on a per-particle basis. To test the relevance of these
findings at physiological levels of ApoF expression, we performed
efflux studies on apo B-depleted serum obtained from the ApoF
knockout mice. To examine ABCG1-mediated efflux, we used
BHK cells stably transfected with ABCG1 driven by a mifepris-
tone-inducible promoter [26]. In this cell system, ABCG1-
mediated efflux is assessed as the difference between cells treated
with and without mifepristone. ABCG1-mediated efflux was not
significantly different between wild type and ApoF KO mice in
either sex (Figure 6A). To assess ABCA1-mediated efflux, we used
J774 macrophages treated with cyclic AMP to upregulate ABCA1
expression. ABCA1-mediated efflux was calculated as the
difference in efflux between cells treated with cAMP, and wells
treated without cAMP for each sample. ABCA1-mediated efflux
was not significantly altered in the female ApoF KO mice.
Surprisingly, we did observe a modest but statistically significant
reduction in ABCA1-mediated efflux in samples from the male
ApoF KO mice relative to control animals (Q0.66%, p=0.027).
Figure 3. Generation of Apolipoprotein F Deficient Mice. A. Schematic diagram (not to scale) showing the wild type and deleted ApoF alleles.
Features are depicted as follows: Exons- white arrows, Beta galactosidase reporter gene- ‘‘LacZ’’ black arrow, PGK promoter- grey arrow, Neomycin
resistance gene- ‘‘Neo’’ black arrow, BamHI restriction sites- vertical lines, and the location of Southern Blotting probe- asterisk. B. Southern blot
confirming successful targeting and genomic location of null allele: WT allele yields a 3.9 kb band, while the Null allele is 2.4 kb. The left panel
contains ES cell DNA, while the right panel depicts livers from the mice. C. Real Time RT-PCR data on ApoF mRNA in the livers of female wild type (+/
+), heterozygous (+/2), and homozygous (2/2) ApoF deficient mice.
doi:10.1371/journal.pone.0031616.g003
Apolipoprotein F Knockout Mice
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We generated mice with a targeted deletion of the ApoF gene in
order to investigate its effects on HDL cholesterol metabolism.
ApoF KO mice were viable and fertile, and had no gross changes
in HDL cholesterol levels, size, or lipid composition on a chow
diet. This is perhaps a bit surprising since we previously found that
overexpression of apoF reduces HDL-C in mice by accelerating
clearance from the circulation [14]. The lack of an HDL
phenotype in the knockout mice suggests that either 1) apo F is
not a major player in HDL metabolism in vivo at physiological
levels of expression, or 2) less likely, compensatory changes or
redundancy mask the impact of apo F deficiency. We have also
attempted to evoke an HDL phenotype using a variety of dietary
manipulations including high fat diet, high cholesterol diet, and
ezetimibe feeding. In all cases examined, HDL-C and other
plasma lipid levels did not substantially vary by genotype. It should
be noted that apo F is known to be repressed by high fat feeding in
mice [27], as well as hamsters [17]. While high fat feeding is a
straight forward way to increase HDL in mice, transcriptional
repression of apo F by high fat could be simplistically expected to
diminish any lipid differences between WT and KO mice.
Likewise, dietary cholesterol loading and sterol depletion with
ezetimibe both failed to reveal lipid differences by genotype. Since
about 25% of the circulating apo F is also found on LDL in human
plasma, additional studies may be warranted to examine the effects
of apo F on apo B lipoprotein metabolism in other mouse models
such as LDL receptor knockout or ApoE knockout mice.
Mouse apo F shares considerable homology (61% AA identity)
with human apo F, and is processed and secreted in a similar
manner. In agreement with findings in other species [5,17], mouse
apoF was expressed at far greater levels in liver than in any of the
other whole tissues examined. It is possible that local expression of
ApoF may play an important role in steroidogenic or exocrine
tissues, and this may warrant further investigation in specific cell
populations. In terms of the plasma pool of ApoF, the data
suggests that the liver is by far the most important contributor to
ApoF mass present on circulating lipoproteins. We found that
mature mouse apo F exists in plasma as an approximately 32 kDa
protein, and is modified with both N- and O-linked sugars. Mouse
apo F has a single N-linked glycosylation site (N206) at a different
location in the mature protein than human apoF (N267). Although
the proteins are fairly well conserved at the amino acid level,
differences in glycosylation patterns may hint at a divergence in
function.
In humans, apo F exists in plasma at concentrations in the range
of 80 mg/ml (similar to that for apo E), of which ,60 mg/mL
should reside on HDL. Assuming a plasma protein concentration
of 1.34 g/L apoA-I for men [28], and an average of roughly 2.5
molecules of apoA-I per HDL particle [29], we estimate that a
theoretical maximum of 1 in 9 HDL particles could potentially
contain ApoF. While not exceedingly abundant, this is in the range
where apo F could realistically be expected to alter HDL levels-
either by affecting receptor mediated uptake, or by influencing
lipid transfer in or out of the particle. We were not able to detect
endogenous mouse apo F, and therefore cannot estimate the
normal abundance of this protein in mouse plasma. Our inability
to detect endogenous mouse ApoF in plasma may be due to
limitations of the antibody, which was raised in rabbits against a
bacterially expressed mouse apo F proprotein. Since sugar
accounts for greater than half the apparent molecular weight of
apo F, it is plausible that the epitopes of plasma apo F recognized
by the antibody may be covered up or otherwise sterically
obstructed by carbohydrate.
We previously found that plasma from mice overexpressing apo
F was more efficient at promoting macrophage cholesterol efflux
on a per-particle basis [14]. ABCG1-mediated efflux was not
significantly different in ApoF KO mice of either sex. Interestingly,
ABCA1-mediated efflux was modestly but significantly lower in
the male ApoF KO mice relative to WT controls. This relatively
small difference, albeit sex-specific to males, is consistent with our
previous results obtained in the setting of ApoF overexpression. It
is worth noting that the absolute amount of ABCA1-mediated
efflux from J774 macrophages to mouse plasma was in the range
of 0 to 2%, in contrast to total efflux values of 10–12% in the
presence of cAMP. This was a consistent result and may be due to
a relatively low concentration of pre-beta HDL in mouse plasma
compared to human plasma. It is not clear how loss of ApoF, a
protein normally found on larger HDL (but oddly enough of
HDL3 density), would affect ABCA1-mediated efflux.
The reduced ABCA1-mediated efflux in the male ApoF KO
mice may suggest a potential protective role for ApoF in
atherosclerotic disease. However, without information on the
absolute abundance of mouse apoF in plasma, it is difficult to
extrapolate these data to the human situation. At the population
level, variation in the CETP gene is the single greatest genetic
determinant of HDL cholesterol levels in the humans [30]. The
Figure 4. X-Gal staining of tissues from ApoF KO mice
harboring a beta-galactosidase reporter gene. The targeted
ApoF allele contains a beta-galactosidase reporter gene in place of
ApoF. X-gal staining was performed on a wild type (WT) and an ApoF
KO mouse (KO) to examine ApoF expression. The wild type mouse is
included for an estimation of background staining for each tissue in the
absence of beta-galactosidase.
doi:10.1371/journal.pone.0031616.g004
Apolipoprotein F Knockout Mice
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be very different in humans, where apo F is believed to be an
endogenous inhibitor of CETP activity. It was recently shown that
apo F levels in HDL were significantly reduced in a small set of
subjects with CAD [31]. In this same report, apo F protein levels
were increased after one year of combined statin and niacin
treatment, suggesting apo F is associated with a favorable
proteomic signature for HDL. Variation within the human ApoF
gene is rare in most populations, but a systematic analysis of ApoF
genetic variants, proteins levels, and CAD status in a large cohort
is clearly warranted to inform about the biology of this cryptic
protein in humans.
Two previous studies have implicated variation at the ApoF
locus in mouse physiology. A genetic screen between SM and NZB
inbred mice identified a region near the ApoF gene at D10Mit271
as a quantitative trait locus (QTL) for PLTP activity [27].
Although coding differences between the strains were observed for
ApoF, its candidacy as the gene underlying this QTL is
questionable considering the proximity of this linkage peak to
the Farnesoid X Receptor (FXR) gene, whose expression varies
10-fold between the strains. FXR is a nuclear receptor known to
directly activate transcription of the PLTP gene [32]. PLTP
deficiency is known to have major effects on HDL size and
quantity in mice [33]. If apo F were a bona fide inhibitor of PLTP
transfer in mice, we would have expected to observe at least a
subtle effect on HDL size or lipid composition.
Another study examined the genetic determinants of leukemia
virus inactivating factor (LVIF) activity in mice [34]. LVIF is a
believed to be a lipoprotein associated protein with the ability to
inactivate murine leukemia viruses- either by itself or with the
particle on which it resides [35,36,37]. An intercross between
strains with and without serum LVIF activity identified a strong
single linkage peak at D10Mit35, near the ApoF gene. However,
apo F expression did not vary between the strains and sequencing
revealed no differences in the coding regions of apo F. The authors
suggested that LVIF activity is likely under the control of a distinct,
but closely linked gene. It is interesting to note that Apolipoprotein
N (Apo N) resides only 12 kb upstream of ApoF in the mouse. Apo
Table 1. Plasma lipid parameters in Apolipoprotein F knockout mice.
Females Males
WT Het KO WT Het KO
Total Cholesterol (mg/dl) 83+/298 7 +/217 81+/213 93+/210 96+/299 3 +/212
HDL Cholesterol (mg/dl) 53+/275 8 +/211 52+/210 62+/29 70+/27* 64+/28
Non-HDL Chol. (mg/dl) 30+/252 9 +/263 0 +/283 1 +/282 6 +/282 9 +/28
Triglycerides (mg/dl) 28+/210 22+/292 6 +/210 43+/218 31+/212* 33+/211*
Cholesteryl Ester (mg/dl) 45+/29 54+/210* 49+/212 50+/27 56+/28* 53+/29
Free Cholesterol (mg/dl) 38+/210 33+/210 32+/294 3 +/274 0 +/293 9 +/29
Body Weight (g) 17.4+/21.8 18.3+/21.3 17.8+/21.3 23.3+/22.2 22.3+/22.3 23.4+/22.3
Liver Weight (g) 0.94+/20.23 1.04+/20.21 0.96+/20.14 1.32+/20.19 1.34+/20.14 1.38+/20.21
Liver: Body Weight % 5.3+/20.8 5.7+/21.3 5.4+/20.6 5.7+/20.5 6.0+/20.4 5.9+/20.8
Liver Cholesterol (mg/g) 2.9+/20.2 2.7+/20.3 4.9+/20.8* 2.9+/21.2 2.5+/20.5 3.6+/20.7
Liver Free Cholesterol (mg/g) 1.7+/20.2 1.5+/20.1 1.5+/20.2 ND ND ND
Liver Cholesteryl Ester (mg/g) 1.2+/20.3 1.2+/20.4 3.4+/20.9* ND ND ND
Lipids were measured in fasting plasma from male Apolipoprotein F wild type (WT), heterozygous (Het), and knockout (KO) on a chow diet at 9–12 weeks of age. Data
are reported as the mean +/2 standard deviation for multiple mice of each genotype. Animal numbers are as follows: Plasma lipids n$15 per group, Body and liver
weights n$5 per group, Liver cholesterol n$4 per group. The asterisk (*) indicates p,0.05 relative to wild type by One way ANOVA, Tukey’s posttest. ND indicates not
determined.
doi:10.1371/journal.pone.0031616.t001
Table 2. Blood Chemistry Parameters in ApoF KO mice.
Females Males
Reference Intervals for
Mouse Blood
WT (n=4) KO (n=5) WT (n=12) KO (n=6)
Sodium (mmol/L) 143+/20.9 141+/21.1 152+/213 142+/21.4 124–174
Potassium (mmol/L) 5.8+/20.8 5.5+/20.5 5.6+/20.7 5.2+/20.2 4.6–8
Creatinine (mg/dl) 0.2+/20.0 0.2+/20.0 0.2+/20.0 0.2+/20.0 0.2–0.8
BUN (mg/dl) 28+/22.2 28+/23.0 30+/24.5 32+/24.5 18–29
AST (U/L) 85+/222 100+/264 103+/281 68+/217 59–247
ALT (U/L) 46+/266 0 +/211 51+/212 45+/27 28–132
Blood was collected in Lithium-Heparin tubes and used to measure classical chemistry parameters. Sodium, Potassium, Creatinine, Blood Urea Nitrogen (BUN), Aspartate
Aminotransferase (AST), and Alanine Aminotransferase (ALT) were measured on a clinical chemistry analyzer. Data is reported as the mean +/2 standard deviation. A
two-tailed t-test was used to compare between genotypes by sex, and no statistically significant differences were found.
doi:10.1371/journal.pone.0031616.t002
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sequence homology to apo F in the proprotein region, although
the mature form of apo N has no similarity to mature apo F.
Interestingly, apo N is a nonfunctional pseudogene in humans due
to a frameshift mutation that gives rise to a stop codon before the
mature protein. It is possible that apo N may be the true LVIF
gene in mice. It is also tempting to speculate that functional
redundancy may exist between apo F and apo N, and that they
may reside on HDL to perform similar functions. Further work is
needed to explore potential roles of these genes in inflammation
and innate immunity. We conclude that mouse apo F is not a
major player in HDL metabolism in mice, and it likely resides on
the HDL particle for a reason distinct from lipid transport. The
apo F deficient mice will be an invaluable tool in deciphering the
true function of apoF-containing HDL, and offer important clues
about the role of apo F in cardiovascular disease.
Materials and Methods
Ethics Statement
All animal procedures were performed according to the
regulations of, and with the prior approval of, the University of
Table 3. The effects of High fat feeding on plasma lipids in ApoF deficient mice.
Genotype
Cholesterol
(mg /dl)
HDL-C
(mg/dl)
Non HDL-C
(mg/dl)
Triglycerides
(mg/dl)
Cholesteryl
Ester (mg/dl)
Free Cholesterol
(mg/dl)
WT 79+/265 3 +/252 6 +/222 5 +/265 0 +/252 9 +/26
Baseline Het 79+/275 4 +/262 5 +/221 8 +/265 4 +/262 6 +/25
KO 76+/210 53+/272 4 +/252 3 +/275 3 +/28 23+/22*
WT 126+/289 5 +/263 1 +/252 5 +/227 89+/210 37+/28
2 weeks Het 120+/214 93+/282 7 +/212 12+/24* 81+/213 40+/27
KO 121+/211 92+/210 29+/23 11+/21* 90+/210 32+/23
WT 125+/299 2 +/283 4 +/233 1 +/278 2 +/210 43+/24
4 weeks Het 122+/210 90+/273 3 +/25 16+/24** 84+/273 8 +/25
KO 116+/278 4 +/263 2 +/23 16+/26** 79+/263 7 +/22
WT 131+/289 8 +/273 3 +/252 1 +/288 2 +/284 8 +/23
9 weeks Het 132+/299 7 +/293 5 +/242 1 +/248 6 +/274 7 +/23
KO 124+/278 8 +/263 6 +/232 0 +/257 8 +/264 6 +/26
Female ApoF wild type (WT), heterozygous (Het), and knockout (KO) mice were bled for baseline lipid measurements and placed on a diet containing 45% kcal from fat
for 9 weeks. Plasma was then collected after 2, 4, and 9 weeks on the diet. All mice were fasted 4 hours before bleeding at every time point. Values are reported as the
mean +/2 standard deviation for each group (WT n=8, Het n=10, KO n=8).
Two Way ANOVA Results:
Cholesterol: Time p,0.0001.
HDL-C: Time p,0.0001.
Non HDL-C: Time p,0.0001.
Triglycerides: Time n.s.,Genotype p=0.0025 (Bonferroni vs WT: * p,0.05, ** p,0.01).
CE: Interaction p=0.0428, Time p,0.0001.
Free Chol: Time p,0.0001, Genotype p=0.0003 (Bonferroni WT vs KO *p,0.05).
doi:10.1371/journal.pone.0031616.t003
Table 4. The effect of cholesterol loading and depletion on plasma lipids in ApoF KO mice.
0.01% Ezetimibe 0.2% Cholesterol
WT KO WT KO
‘‘n’’ 6 6 4 5
Total Cholesterol (mg/dl) 70+/267 7 +/297 9 +/210 86+/214
HDL Cholesterol (mg/dl) 45+/244 9 +/244 5 +/244 9 +/25
Non HDL Cholesterol (mg/dl) 25+/232 8 +/273 4 +/263 7 +/210
Triglycerides (mg/dl) 38+/26 30+/24* 23+/242 4 +/25
Body Weight (g) 18.4+/20.6 19.3+/20.9 19.4+/21.8 20.2+/20.8
Liver Weight (g) 0.96+/20.5 0.97+/20.10 1.11+/20.12 1.05+/20.07
Liver : BW (%) 5.2+/20.1 5.0+/20.3 5.8+/20.9 5.2+/20.4
Liver Cholesterol (mg/g) 3.2+/20.7 3.8+/20.4 3.9+/20.4 4.8+/20.6
ApoF wild type (WT) and knockout (KO) mice (9–10 weeks of age) were fed a chow diet supplemented with either 0.01% ezetimibe or 0.2% cholesterol for 11 days.
Values are reported as mean +/2 standard deviation.
*P,0.05 relative to WT for each treatment group.
doi:10.1371/journal.pone.0031616.t004
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protocol number 706003.
Generation of Apolipoprotein F Deficient Mice
We obtained embryonic stem cells harboring a null ApoF allele
from the knockout mouse project (www.komp.org). The ZEN-Ub1
cassette, which contains a Beta Galactosidase Reporter gene
followed by a Neomycin resistance gene driven by the phospho-
glycerate kinase (PGK) was inserted into the ApoF locus, such that
the entire coding sequence and single intron of the gene were
replaced. This was done in VGB6 ES cells, which are derived from
C57BL/6NTac mice. We obtained three clones termed 10417A-
D6, 10417B-H8, and 10417A-H2- which were determined to be at
least 79%, 68% and 45% euploid respectively. The ES cells were
expanded in growth media containing 15% ES grade serum
(Hyclone), 2 mM L-glutamine, 1 mM Non-essential amino acids,
1 mM sodium pyruvate, 8 ml/ml b-mercaptoethanol, 1610
7 U/L
Leukemia Inhbitory Factor (LIF) from ESGRO, and 16
Penicillin/Streptomycin cocktail in DMEM (Gibco). ES cells were
plated on top of feeder layers of primary mouse embryonic
fibroblasts (Millipore, PMEF-N), in 6-well surface modified
polystyrene plates (Beckman 353846), and were split at least once
every three days. Following confirmation of genotype by Southern
blotting, the ES cells were delivered to the Penn Transgenic and
Chimeric Mouse Facility for Microinjection. Clone 10417A-D6
was injected into 41 Balb/c blastocyts which were implanted into
four pseudopregnant recipients. Three male chimeras were
obtained- 90%, 85%, and 70% by coat color, and mated with
C57BL6/J female mice. One chimeric mouse (90% chimerism)
successfully transmitted the null ApoF allele in the germline and
was used to found a colony by breeding to multiple C57BL6/J
females. ApoF knockout mice were viable and obtained in the
expected 1:3 Mendialian ratio from breedings of heterozygous
mice. No breeding or fertility problems were observed in the
homozygous null mice. All wild type C57BL6 control mice were
bred and maintained in house, and matched for sex and age in all
experiments. No differences in lipids were observed between WT
or ApoF KO mice obtained by Het to Het breeding versus those
obtained from homozygote to homozygote breeding.
Animals
Mice were housed in an AAALAC accredited animal facility in
polycarbonate cageswith filter tops. Mice were maintained on a
light cycle from 6 am to 6 pm, and had free access to food and
water. Mice were maintained on a chow diet (Purina LabDiet
5010) unless otherwise indicated. Mice were also fed a high fat diet
containing 45% kcal from fat (D12451i, Research Diets) for 9
Figure 5. HDL cholesterol content, size, and apoprotein
composition in ApoF KO mice. A. Gel filtration chromatography
of 150 microliters of pooled plasma from wild type (WT), and ApoF KO
(KO) mice. B. HDL size of plasma from wild type (WT), heterozygous
(Het) and homozygous ApoF KO (KO) mice as determined by NMR
analysis. C. Denaturing SDS-PAGE gel of proteins from HDL
(1.063,d,1.21) centrifugally isolated from wild type and ApoF
knockout mice. Ten micrograms of HDL protein was electrophoresed
on 12% Bis-Tris gels and subjected to staining with Coomassie blue. The
identity of albumin, apo E, apo A-I, apo A-II, and apo C’s were
determined by comparison to standards of human LDL, HDL and whole
plasma. The 13 kDa band present in the wild type HDL but diminished
in the KO was found to contain Apo N and B-globin as the primary
protein components by LC-MS.
doi:10.1371/journal.pone.0031616.g005
Table 5. Lipoprotein Composition in ApoF KO mice.
Fraction Genotype Protein Cholesteryl Ester Free Cholesterol Triglycerides Phospholipids
VLDL WT 37.4+/24.8 1.6+/20.3 1.6+/20.1 55.2+/25.3 4.3+/21.3
KO 44.3+/26.2 1.4+/20.1 1.3+/20.4 49.3+/26.7 3.7+/21.2
IDL/LDL WT 21.8+/21.2 8.3+/22.0 9.3+/20.4 45.8+/24.0 14.7+/21.4
KO 24.6+/23.1 8.5+/22.2 10.5+/21.6 38.6+/24.3 17.8+/210
HDL WT 48.6+/20.9 22.7+/21.1 5.6+/20.2 0.62+/20.06 22.4+/20.4
KO 47.7+/21.1 20.8+/22.4 5.9+/20.8 0.72+/20.21 24.9+/22.7
Lipoproteins were isolated from one milliliter of pooled mouse plasma by KBr density gradient ultracentrifugation as follows: VLDL d,1.006, IDL/LDL 1.006,d,1.063,
HDL 1.063,d,1.21 g/mL. Concentrations for each lipid are given as the percentage of total mass in the fraction. Values are reported as the mean +/2 standard
deviation of three separate isolations (n=3), with each value representing a separate and distinct pool of at least four mice per genotype.
doi:10.1371/journal.pone.0031616.t005
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ed with either 0.2% cholesterol (Research Diets C16014) or 0.01%
ezetimibe (Research Diets C16012i) for 11 days as indicated in the
text. Mice were fasted for four hours prior to sacrifice and bleeding
for lipid analysis. Animals were sacrificed at 10–12 weeks of age,
with the exception of those animals challenged with a high fat diet,
ezetimibe diet, or cholesterol-enriched diet. In these cases, feeding
began at 10–12 weeks of age, and the mice were sacrificed
immediately after the indicated feeding regimen. Blood was
collected in heparinized Natelson collection tubes by retro-orbital
bleeding. Plasma was isolated by centrifugation at 16,000 g for
7 minutes at 4uC in a bench top microcentrifuge.
Southern Blotting
Genomic DNA was isolated from confluent wells of ES cells by
lysis in a buffer containing 100 mM EDTA, 60 mM Tris pH 7.5,
0.1% SDS, and 200 mg/mL Proteinase K. DNA was extracted by
adding an equal volume of phenol pH 7.0 (Ameresco), and an
equal volume of chloroform:isoamyl alcohol (24:1) in a 50 mL
polypropylene conical. The same lysis buffer was used to isolate
genomic DNA from mouse livers following ultracentrifugal
isolation of nuclei as previously described [38]. Samples were
gently rocked for 10 minutes and then centrifuged at 2000 rpm in
a bench top centrifuge to separate the phases. The viscous aqueous
upper phase was transferred using a cut off 1 mL pipet tip to a new
50 mL conical tube. The DNA was then re-extracted with 2
volumes of chloroform isoamyl alcohol (24:1). One tenth volume
of 3M sodium Acetate (pH 7.0) was added to the DNA and
thoroughly mixed in by swirling. The DNA was layered with 2.5
volumes of ice cold ethanol, and spooled by rapid swirling with a
hooked Pasteur pipet at the water/ethanol boundary. The spooled
DNA was removed from the Pasteur pipet by appling 1–2 mL of
TE buffer (10 mM Tris pH 7.5, 0.1 mM EDTA) dropwise with a
1 mL pipetman. DNA was dissolved by gentle rocking overnight at
4uC. Aliquots of the DNA were digested overnight at 37uC with 10
Units/mlo fBamHI (New England Biolabs) in the buffer
recommended by the manufacturer. Fifty micrograms of DNA
were electrophoresed on a large 0.9% agarose gel in Tris Acetate
EDTA (TAE) running buffer. The gel was stained with Ethidium
bromide, photographed, and transferred by upward capillary
transfer to a Nylon membrane. A short DNA probe corresponding
to a 314 bp sequence downstream of the ApoF gene was obtained
by PCR using the following primers: Forward 59-GGT CCT TGA
ACC GCT TGG AGA ATT G-39, Reverse 59-GGC TTA TGA
CAA GGA TCA TAA TGG GTA CAT AG-39. Fifty nanograms
of probe DNA was labeled with 50 mCi of
32P-alpha-dCTP using
the High Prime Labeling Kit (Roche). The membrane was
hybridized with the denatured DNA probe in ExpressHyb
Solution (Clontech) containing 0.2 mg/mL sonicated salmon
sperm DNA (Stratagene) at 50uC for 2 hours. The membrane
was then washed twice for 10 minutes each in 26 Sodium
Chloride/Sodium Citrate (SSC) with 0.5% SDS, followed by two
Figure 6. Cholesterol efflux capacity of HDL fractions from ApoF KO mice. Serum was collected from wild type and ApoF KO mice for the
measurement of cholesterol efflux capacity.. Apo B lipoproteins were precipitated with polyethylene glycol, and the resulting supernatant (containing
HDL and other soluble serum proteins) was tested for its ability to promote cholesterol efflux as described in the methods section. A. ABCG1-
mediated cholesterol efflux to apo B-depleted serum from wild type (WT) and ApoF knockout (KO) mice. B. ABCA1-mediated cholesterol efflux.
doi:10.1371/journal.pone.0031616.g006
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then allowed to expose autoradiography film (Kodak X-OMAT
LS) with a BioMax intensifying screen at 280uC for 1–3 days.
RNA Isolation and Realtime RT-PCR
Approximately 20 milligrams of liver was placed into 2.0 mL
cryotubes (Sarstedt) and rapidly flash frozen in liquid nitrogen. A
steel bead and 1 mL of Trizol reagent (Invitrogen) were added to
each cryotube. The livers were homogenized using a TissueLyzer
bead mill homogenizer (QIAGEN) for 5 minutes at 25 Hz. Total
RNA was isolated according to the standard Trizol procedure
(Invitrogen). RNA concentrations and purity were determined
using a UV NanoSpec device. One microgram of total RNA was
reverse transcribed using random hexameric primers with the
Superscript III RT Kit from Invitrogen according to the
manufacturer’s instructions. Predesigned TaqMan primer/probe
sets from Applied Biosystems were used to detect mouse ApoF
(Mm00506066_g1) and Beta Actin (4352341E). Reactions were set
up containing 12.5 mlo f2 6 Taqman reaction mix, 0.5 mlo f
primer/probe, and 5 mL cDNA (diluted 1:20) in a final volume of
25 mL. PCR conditions were 95uC for 5 minutes, then 95uC for
1 minute and 60uC for 30 seconds, cycled 40 times. The relative
quantity of ApoF mRNA was calculated using the delta delta CT
method with B-Actin as the housekeeping gene.
X-Gal Staining of Tissues
Whole tissues were harvested from mice after perfusion with
PBS. The individual tissues were separately placed in 20 ml glass
vials and fixed in 10 volumes of 2% paraformaldehyde (Electron
Microscopy Services) for one hour with rocking at 4uC. The tissues
were then washed 6 times with 10 volumes of PBS for 20 minutes
each. Tissues were then incubated with the X-gal substrate
overnight at 37uC in a buffer containing PBS with 0.1%
deoxycholic acid, 2 mM MgCl2, 5 mM Potassium Hexacyanofer-
rate (iii) (Sigma 244023), 5 mM Potassium Hexacyanoferrate (ii)
(Sigma P9387), 0.1% NP40, and 1 mg/ml X-gal.
Cell Culture
Adherent HEK293 cells (obtained from the American Type
Culture Collection; www.atcc.org) were grown in DMEM with
10% FBS, and 1% Pen/Strep as previously described [39].
Confluent wells of HEK293 cells in 6 well plates were transiently
transfected Lipofectamine 2000 according to the manufacturer’s
instructions. The day after the transfection, media was switched to
OPTI-MEM low serum media (Invitrogen). Media was collected
48 hours later and frozen. Cells were washed 26with PBS, and
lysed in 1 mL of 16 LDS buffer (Invitrogen). Cell lysates were
freeze-thawed and vortexed to clear debris, and then boiled and
subjected to Western Blotting.
Enzymatic Deglycosylation
Plasma was obtained from mice overexpressing mouse ApoF
two weeks after the administration of 5610
11 genome copies (GC)
of our previously described AAV8-TBG-mApoF vector [14].
Enzymatic deglycosylation of plasma proteins was accomplished
using the PROZyme kit from Glyko (catalog number GK80115).
Briefly, 7 mL of plasma was diluted with 10 mLo f5 6incubation
buffer and 2.5 mL denaturation solution to a final volume of
32.5 mL with water. The samples were denatured at 100uC for
5 minutes in boiling water, and allowed to cool. Detergent solution
(2.5 mL) was added to each tube and mixed. Next, PNGAse F
(1 mL), Sialidase A (1 mL), and O-glycanase (1 mL) were added to
each tube in the combinations shown in Figure 1, with the
remaining volume filled with water. The denatured samples were
digested for 3 hours in a 37uC water bath. The reactions were
terminated with the addition of 50 mLo f2 6 Western Sample
Buffer (6 M Urea, 3% SDS v/v, 0.2 M sucrose, 5% b-
mercaptoethanol, 60 mM Tris pH 6.8, and 0.005% bromophenol
blue) and immediately frozen until Western blotting was
performed.
SDS-PAGE and Western Blotting
Cell lysates prepared in 16LDS sample buffer were aliquotted
and then received 1/10
th volume of 106 reducing agent
(Invitrogen). Conditioned media collected from cells was com-
bined with 46 LDS sample buffer and 106 reducing agent to
volume. Dialyzed HDL (10 mg protein/lane) was diluted with 46
LDS sample buffer and run without reducing agent. Samples were
denatured by boiling in water for 5 minutes and loaded (fifteen
microliters per well) on NuPAGE precast Bis-Tris gels, and
electrophoresed in 16MES running buffer (Invitrogen). Proteins
were transferred to nitrocellulose membranes and blocked for one
hour in blocking milk (5% Nonfat dry milk-Carnation, 0.05%
Tween 20, PBS). Antibodies were added for 2 hours to overnight
in blocking milk. The primary antibodies were removed by three
10 minute washes in PBS with 0.05% Tween 20 (PBS-T). Donkey
anti-rabbit Horseradish Peroxidase Conjugated IgG (GE Health-
care) was added for two hours at a 1:4000 dilution in PBS-T. The
secondary antibody was removed with 3610 minute washes with
PBS-T. Membranes were developed by chemiluminescene using
the ECL reagent from GE, and allowed to expose film. The rabbit
anti-mouse apo F antibody was a kind gift from Dr. Kaijin Wu and
Dr. Sarah Hamm-Alvarez (University of Southern California).
This antibody was raised against the entire proprotein region of
mouse ApoF that was expressed in E. Coli and affinity purified
[40]. Rabbit anti-mApoF was used at a 1:4,000 dilution. HDL gels
were stainined with 0.1% Coomassie brilliant blue in methanol-
acetic acid water (3:1:6) as previously described [41].
Lipid and Lipoprotein Analyses
Plasma lipids were analyzed on a Roche Cobas-Mira autoan-
alyzer using commercially available reagents from Sigma. For gel
filtration chromatography, one hundred and fifty microliters of
pooled mouse plasma was diluted in 150 mM NaCl w/ 1 mM
EDTA and separated on over two tandem Superose 6 gel filtration
columns (GE Healthcare) using an AKTA FPLC system as
previously described [42]. One hundred microliters of each
500 mL fraction was assayed for cholesterol content using the
WAKO Cholesterol E kit. Nuclear magnetic resonance (NMR)
analysis of plasma was carried out by LipoScience.
Liver Cholesterol Measurements
Liver pieces (250 mg) were homogenized in 750 mL of PBS
using a Tissuelyzer bead mill homogenizer (QIAGEN). The liver
lysates were then diluted 1:5 with PBS by combining 200 mLo f
homogenate with 800 mL PBS. Twenty microliters of the diluted
lysate was pipeted into each well of a 96 well microtiter plate
(Polysorp, NUNC). Lipids were solubilized at 37uC for 5 minutes
with the addition of 20 mL of 0.25% deoxycholic acid solution.
Human serum standards of known cholesterol concentration were
prepared and solubilized in parallel. Infinity Cholesterol Reagent
(200 mL) was added to each well containing standard or liver
lysate, and incubated for 15 minutes at 37uC. The absorbance of
each well was read at 500 nm on a microplate reader. The
concentration of cholesterol (in units of mg cholesterol/g liver) was
calculated by extrapolating from the standard curve [43]. Liver
free cholesterol content was determined according to the method
Apolipoprotein F Knockout Mice
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reagent for quantitation. Liver cholesteryl ester content was
determined by subtracting the free cholesterol from total
cholesterol.
holesterol Efflux Assays
Serum or plasma was collected from wild type and ApoF
knockout mice. ApoB lipoproteins were precipitated as previously
described [45]. Briefly, serum was mixed with 0.4 volumes of PEG
solution containing 20% PEG 8000 MW (Sigma P-2139) and
200 mM Glycine pH 7.4. The precipitation reactions were
incubated at room temperature for 20 minutes, and then
centrifuged at 16,000 g for 30 minutes at 4uC. The resulting
supernatant, containing HDL and other serum proteins, was set
aside for efflux assays. Cholesterol efflux assays were performed as
previously described [46,47]. J774 cells were used to assess ABCA1
mediated efflux. J774 cells (obtained from the American Type
Culture Collection; www.atcc.org) were grown in RPMI media
containing 20% FBS at plated at a density of 70,000 cells per well
in 24-well plates as previously described [46]. Cells were labeled
for 24 hours with 2 mCi/ml [1,2-
3H] cholesterol (PerkinElmer) in
5% FBS-RPMI. Following labeling, J774 cells were treated +/
20.3 mM c-AMP (cpt-AMP, Sigma) in 0.2% BSA for 16–18 h to
upregulate ABCA1. Efflux to 2.8% PEG supernatants (ApoB
depleted sera) in RPMI with 0.2% BSA was performed for four
hours. All reactions were performed in triplicate, and the values
were averaged for each sample. ABCA1-mediated efflux was
calculated as the difference between cells treated with cAMP and
those treated without cAMP. ABCG1 mediated efflux was
measured using BHK cells stably transfected with ABCG1 under
the control of a mifepristone inducible promoter [26] (gift from
Dr. Jack Oram, University of Washington School of Medicine).
BHK cells were plated in 24 well plates at a density of 125,000
cells per well. Following labeling with 1 mCi/ml [1,2-
3H]
cholesterol, the cells were treated for 16 hours with 10 nM
mifepristone to upregulate ABCG1 expression. Efflux was
performed over 4 hours to 2.8% PEG supernatant (equivalent to
2% serum) in RPMI with 0.2% BSA. ABCG1 mediated efflux was
calculated as the difference in efflux between cells with
mifepristone and those without.
Statistical Analyses
Comparisons between groups were made using a two-tailed
homeoscedastic student’s t-test. Comparisons involving three
groups or more were made by ANOVA, followed by Tukey’s
post test to compare between groups where differences existed. P
values less than 0.05 were considered statistically significant, and
are noted with an asterisk (*) in the figures. For comparisons
involving multiple groups and time points, two way ANOVA was
performed, followed by Bonferroni’s posttest to compare to the
wild type where differences existed.
Supporting Information
Figure S1 Real time RT-PCR standard curves. Liver
cDNA was pooled and serially diluted 1:4 to determine the log-
linear range of the assay. The diluted cDNA was used as a
template to measure ApoF or B-Actin expression with Taqman
primers and probes as described in the methods section. The
threshold cycle (Ct) is shown on the y-axis, and the relative
quantity of cDNA template is shown on the x-axis. A linear
regression was performed to determine the log-linear range of the
assay. A. ApoF Taqman primer and probe B. B-Actin Taqman
primer and probe.
(TIFF)
Table S1 Threshold Cycles for ApoF and Beta Actin in
male wild type mice. One microgram of RNA was reverse
transcribed to cDNA in a final volume of 20 mL. The resulting
cDNA was diluted 1:25 in the final reaction volume. Relative
quantities were calculated using the delta delta Ct method, and are
given to relative liver which is normalized to an arbitrary value of
1,000,000. Relative quantities are reported as the mean +/2
standard deviation for each tissue.
(PDF)
Table S2 Threshold Cycles for ApoF and Beta Actin in
female wild type mice. One microgram of RNA was reverse
transcribed to cDNA in a final volume of 20 mL. The resulting
cDNA was diluted 1:156 in the final reaction volume. Relative
quantities were calculated using the delta delta Ct method, and are
given to relative liver which is normalized to an arbitrary value of
1,000,000. Relative quantities are reported as the mean +/2
standard deviation for each tissue.
(PDF)
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